FDA批准波士顿科学公司的AI动力装置, 以提高心律失常治疗精确度。 FDA approves Boston Scientific’s AI-powered device to enhance heart arrhythmia treatment precision.

波士顿科学公司已经获得林业发展局批准FARAPULSE系统,这是一个AI动力装置,旨在通过实时数据分析指导通缩程序,改善心脏心律失常治疗。 Boston Scientific has received FDA approval for the FARAPULSE system, an AI-powered device designed to improve heart arrhythmia treatments by guiding ablation procedures with real-time data analysis. 这项技术旨在提高精度,缩短手术时间,减少心房动等疾病的微创手术并发症. The technology aims to increase precision, shorten procedure times, and reduce complications during minimally invasive surgeries for conditions like atrial fibrillation. 在该公司向智能心血管工具推进的过程中,该系统预计将在未来几个月在选定的美国医疗中心推出,尽管价格和确切部署时间表仍未披露。 Part of the company’s push toward intelligent cardiovascular tools, the system is expected to roll out in select U.S. medical centers in the coming months, though pricing and exact deployment timelines remain undisclosed. 这项核准反映了人工智能在医疗装置中的结合日益加强,对病人护理和保健效率具有潜在好处。 The approval reflects the growing integration of artificial intelligence in medical devices, with potential benefits for patient care and healthcare efficiency.